Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nicholas D. James, Johann S. De Bono, Melissa Ruth Spears, Noel Clarke, Malcolm David Mason, David P. Dearnaley, Alastair W S Ritchie, J. Martin Russell, Clare Gilson, Robert J. Jones, Silke Gillessen, David Matheson, San Aung, Alison J. Birtle, Simon Chowdhury, Joanna Gale, Zafar Malik, Joe M. O'Sullivan, Mahesh K B Parmar, Matthew Robert Sydes
Institutions: Coventry (United Kingdom), Institute of Cancer Research, Royal Marsden Hospital, MRC Clinical Trials Unit at UCL, University College London, The Christie Hospital, The Christie NHS Foundation Trust, Cardiff University, University of Glasgow, Beatson West of Scotland Cancer Centre, Kantonsspital St. Gallen, Leeds Beckett University, Royal Devon and Exeter Hospital, Royal Preston Hospital, St Thomas' Hospital, King's College Hospital, Portsmouth Hospitals NHS Trust, Clatterbridge Cancer Centre NHS Foundation Trust, Belfast City Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4253077057